Century Therapeutics Inc. (IPSC)
Century Therapeutics Statistics
Share Statistics
Century Therapeutics has 86.05M shares outstanding. The number of shares has increased by 1.83% in one year.
| Shares Outstanding | 86.05M |
| Shares Change (YoY) | 1.83% |
| Shares Change (QoQ) | 1.19% |
| Owned by Institutions (%) | 42.97% |
| Shares Floating | 38.84M |
| Failed to Deliver (FTD) Shares | 4.98K |
| FTD / Avg. Volume | 1% |
Short Selling Information
The latest short interest is 3.02M, so 3.56% of the outstanding shares have been sold short.
| Short Interest | 3.02M |
| Short % of Shares Out | 3.56% |
| Short % of Float | 8.69% |
| Short Ratio (days to cover) | 5.01 |
Valuation Ratios
The PE ratio is -0.63 and the forward PE ratio is -0.46. Century Therapeutics's PEG ratio is 0.02.
| PE Ratio | -0.63 |
| Forward PE | -0.46 |
| PS Ratio | 12.06 |
| Forward PS | 1.9 |
| PB Ratio | 0.49 |
| P/FCF Ratio | -0.72 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Century Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.5, with a Debt / Equity ratio of 0.3.
| Current Ratio | 1.5 |
| Quick Ratio | 1.5 |
| Debt / Equity | 0.3 |
| Debt / EBITDA | -0.44 |
| Debt / FCF | -0.44 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $47.06K |
| Profits Per Employee | $-904.04K |
| Employee Count | 140 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1.79M |
| Effective Tax Rate | -1.43% |
Stock Price Statistics
The stock price has increased by -87.3% in the last 52 weeks. The beta is 1.75, so Century Therapeutics's price volatility has been higher than the market average.
| Beta | 1.75 |
| 52-Week Price Change | -87.3% |
| 50-Day Moving Average | 0.68 |
| 200-Day Moving Average | 1.43 |
| Relative Strength Index (RSI) | 28.86 |
| Average Volume (20 Days) | 497.6K |
Income Statement
In the last 12 months, Century Therapeutics had revenue of 6.59M and earned -126.57M in profits. Earnings per share was -1.61.
| Revenue | 6.59M |
| Gross Profit | 6.59M |
| Operating Income | -138.14M |
| Net Income | -126.57M |
| EBITDA | -111.47M |
| EBIT | -124.78M |
| Earnings Per Share (EPS) | -1.61 |
Balance Sheet
The company has 58.44M in cash and 48.96M in debt, giving a net cash position of 9.48M.
| Cash & Cash Equivalents | 58.44M |
| Total Debt | 48.96M |
| Net Cash | 9.48M |
| Retained Earnings | -782.34M |
| Total Assets | 353.22M |
| Working Capital | 64.27M |
Cash Flow
In the last 12 months, operating cash flow was -110.14M and capital expenditures 0, giving a free cash flow of -110.14M.
| Operating Cash Flow | -110.14M |
| Capital Expenditures | 0 |
| Free Cash Flow | -110.14M |
| FCF Per Share | -1.4 |
Margins
Gross margin is 100%, with operating and profit margins of -2096.48% and -1920.87%.
| Gross Margin | 100% |
| Operating Margin | -2096.48% |
| Pretax Margin | -1893.7% |
| Profit Margin | -1920.87% |
| EBITDA Margin | -1691.79% |
| EBIT Margin | -2096.48% |
| FCF Margin | -1671.5% |
Dividends & Yields
IPSC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for IPSC is $5, which is 963.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 963.8% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -3.91 |
| Piotroski F-Score | 3 |